Top Markets
Coin of the day
Pell Bio-Med Technology Co., Ltd. Pell Bio-Med Technology Co., Ltd.

Pell Bio-Med Technology Co., Ltd.

6949
株式のランク #4985
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in... Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio encompasses good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) utilized in regenerative medicine, and both CIK and DC-CIK therapies aimed at combating various cancers. Beyond its existing products, Pell Bio-Med is actively engaged in developing novel pharmaceuticals for diverse cancer types, pioneering cell immunotherapy strategies, and advancing stem cell regenerative therapy techniques. Its research and development efforts extend to cutting-edge areas such as chimeric antigen receptor T cell (CAR-T), CAR-NK, CAR-?dT, and genetically modified ADSC technologies. The company is also progressing product development specifically targeting indications like B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer.
株価
$47.38
最終同期: 2026-08-26
時価総額
$3.11B
変化(1日)
9.96%
変化(1年)
238.59%
TW
取引 Pell Bio-Med Technology Co., Ltd. (6949)

カテゴリー

Pell Bio-Med Technology Co., Ltd.(6949)の利益
2026 時点の利益 TTM: 0
Pell Bio-Med Technology Co., Ltd. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Pell Bio-Med Technology Co., Ltd. の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差
$5.27B -
US
$1.95B -
NL
$-3.09B -
US
$-4.02B -
AU
- -
CH